M7D retweeted
🚨 $LLY FOUNDAYO: DISASTROUS PHASE 3 RESULTS IN JAPAN.
The numbers are brutal. Eli Lilly’s oral obesity drug is delivering roughly HALF the weight loss of $NVO’s oral semaglutide, while suffering massive treatment discontinuation at its highest dose.
ATTAIN-J Phase 3 — 72 weeks, 36 mg:
🔴 Just 7.9% weight loss (treatment-regimen estimand).
🔴 33.3% discontinued treatment at the highest dose. ONE IN THREE patients! Versus 15% on placebo.
🔴 Only 58.8% achieved even 5% weight loss.
🔴 Increasing the dose from 12 mg to 36 mg actually produced WORSE average results: 8.7% vs 7.9%.
Now compare that with $NVO’s oral semaglutide 50 mg in the East Asian OASIS 2 trial:
🟢 14.3% weight loss at 68 weeks.
🟢 84.3% achieved at least 5% weight loss.
🟢 Just 4.5% discontinued because of adverse events.
These are separate trials, not a head-to-head comparison, but the contrast is extraordinary.
Foundayo delivered only 55% of semaglutide’s reported weight-loss efficacy, despite using its highest tested dose.
And the discontinuation numbers raise serious questions about long-term tolerability and commercial persistence.
This is supposed to be Lilly’s next global oral obesity blockbuster?
If these results are replicated across international populations, the commercial implications could be enormous.
The narrative that Lilly will dominate the global oral obesity market deserves serious reconsideration.
A major competitive warning for $LLY. A potentially significant opportunity for $NVO.
$NVO $LLY $VKTX
PALANTIR JUST REPORTED EARNINGS
*PALANTIR 2Q REV. $1.94B, EST. $1.81B ( BEAT ✅ )
*PALANTIR 2Q ADJ EPS 41C, EST. 35C ( BEAT ✅ )
*PALANTIR 2Q ADJ. EBITDA $1.20B, EST. $1.09B ( BEAT ✅ )
*PALANTIR SEES FY ADJ. OPER PROFIT $4.90B, EST. $4.51B ( BEAT ✅ )
$PLTR
M7D retweeted
Fierce Pharma updated its chart tracking $NVO ’s Oral Wegovy and $LLY ’s Foundayo prescriptions.
It is still a thing of beauty for Novo Nordisk.
#stocks #investing #obesity
M7D retweeted
+200 مليون غرامات على مصرف الراجحي في السنتين الماضية !!!
أبرز الغرامات :-
- مخالفة تعليمات البنك المركزي (الإشرافية)
- مخالفة تعليمات البنك المركزي (الخاصة بحماية العملاء)
مجموع مخالفات 2024: 67 مخالفة من البنك المركزي
مجموع مخالفات 2025: 46 مخالفة من البنك المركزي
أيضًا يوجد مخالفة من البلدية بسبب عدم تجديد رخص البلدية.
M7D retweeted
$NVO Novo Nordisk presented strong new data for the Wegovy pill.
✅Early responders (about 29% of users) lost 21.6% of body weight by week 64
✅Even non-early-responders lost a meaningful 11.5%
✅77% of people with poor physical function saw significant improvement in mobility vs. 43% on placebo
They also dropped a comparison against $LLY's Orforglipron:
The Wegovy pill produced greater weight loss, and orforglipron users were about 14x more likely to quit due to GI side effects. (take this with a grain of salt as this is not H2H).
In a patient preference survey, 84% preferred a treatment profile matching Wegovy pill.
The headline trial result (OASIS 4) remains 17% average weight loss vs. 2.7% for placebo over 64 weeks.
M7D retweeted
$LULU Still at zero debt
Price is at $169, ATH at $517
New CEO in now
They still have ZERO DEBT
I would be very surprised if the new CEO does not borrow to buy back shares
M7D retweeted
$NVO $LLY $HIMS
🚨 BREAKING: NOVO SAYS ITS GLP-1 PILL > LILLY'S PILL
84% OF PARTICIPANTS PREFERRED THE $NVO WEGOVY PILL COMPARED TO $LLY FOUNDAYO (ORFORGLIPRON) IN A PATIENT STUDY
NOVO SAYS WEGOVY PILL 25MG SHOWED GREATER MEAN WEIGHT LOSS VS. ORFORGLIPRON 36MG IN POPULATION-ADJUSTED INDIRECT TREATMENT COMPARISON
M7D retweeted
#PRESS The US Food and Drug Administration (FDA) has approved the first and only once-weekly basal insulin treatment for adults with type 2 diabetes. This reduces the burden of daily basal insulin therapy by lowering the number of weekly injections from seven to one.
Learn more in the Company Announcement here:
novonordisk.com/news-and-med…
M7D retweeted
$CRSR performed pretty much as expected. Gaming components and systems margins rose from 18.10% to 30.20%. I am out of my position.
My thesis was to buy as algos pushed the stock higher on the headline beat, then maybe management would mention supply constraints and the stock would come under pressure. Regardless, I'll take the win!
I have been researching $CRSR recently, mostly due to the strong trends for Fanatec. Additionally, search trends for their RAM products have been very strong and could contribute meaningfully to margins. The major risk, which led to tempered guidance for the category, remains supply, as they can't sell what they can't source. Importantly, memory was roughly 34% of Corsair's Q3 revenue. Gamer and Creator Peripherals Segment is a mixed bag and needs further work.
Management Quote:
"This adjustment assumes a conservative outlook for Q4, primarily to account for a tight DDR5 memory market and reflects the latest estimated customer spending patterns. While Corsair has a strong mitigation plan in place for memory availability, we believe it is prudent to temper expectations on the upside in this category."
If the mitigation plans work and they are able to secure supply, Corsair could catch a bid here.
M7D retweeted
الهلال يتصدر قائمة الأندية السعودية من حيث صافي الإنفاق السلبي خلال 10 فترات انتقال حيث بلغ 700 مليون يورو.
(مرصد CIES للدراسات الرياضية)
-
M7D retweeted
$NVO 's Oral Wegovy is taking off in the U.S.
New prescriptions jumped from 4,289 → 20,371 in the first two weeks after launch.
For comparison (week 2):
• Wegovy injection: 1,017
• Zepbound (Eli Lilly): 10,026
Insured patients only.
#StocksInFocus #investing
M7D retweeted
⚖ الحالات التحكيمية لـ #نيوم_الهلال:
-لا وجود لمخالفة على لاعب الهلال، الاستمرار قرار صحيح د45+3
-ركلة جزاء صحيحة للهلال د64
-كان يجب طرد لاعب نيوم لمنع فرصة تسجيل هدف د67
-ركلتا جزاء لم تحتسبتان لنيوم د82 و89
@Abo_zyad_q
#دورينا_غير
#قناة_السعودية
M7D retweeted
Tell me $HIMS is COOKed without telling me they're COOKed... 🔥
M7D retweeted
#PRESS The first GLP-1 pill for the treatment of obesity is now broadly available across America.
Learn more in the press release here: novonordisk.com/content/nnco…
M7D retweeted
💊 حبوب ويغوفي (Wegovy) لإنقاص الوزن
خبر مبشّر لمرضى السمنة 👇
🔹 أول دواء GLP-1 فموي معتمد لعلاج السمنة في أمريكا
🔹 يحقق نزول وزن بمتوسط حوالي 16%
🔹 يساعد على الحفاظ على الوزن وله فوائد قلبية ❤️
⚠️ يُستخدم تحت إشراف الطبيب وليس بديلًا عن نمط الحياة الصحي.
✨ الأمل كبير… وكل يوم يظهر علاج جديد
والخيارات الطبية للسمنة في تطوّر مستمر 🌱
M7D retweeted
تحول تاريخي في إنقاص الوزن..
أمريكا تُجيز أول أقراص من علاج Wegovy لإنقاص الوزن، ومن المتوقع طرح الأقراص في الأسواق بداية عام 2026.
-
M7D retweeted
دراسة حديثة:
تقليص العمل 4 أيام في الأسبوع حسّن الصحة النفسية وقلّل الإرهاق، دون انخفاض في الإنتاجية.
(جامعة بوسطن)
M7D retweeted
#PRESS The first GLP-1 pill for the treatment of obesity is now approved by the US Food and Drug Administration (FDA).
Learn more in our company announcement here: novonordisk.com/content/nnco…





































